Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia

Abstract Background Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such benefit have not been fully understood, and whether empagliflozin can be...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Elena Fortin, Magnus Lundin, Linda Mellbin, Anna Norhammar, Per Näsman, Stina Smetana, Peder Sörensson, Ele Ferrannini, Lars Rydén, Giulia Ferrannini
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2023-08-01
Σειρά:	Cardiovascular Diabetology
Θέματα:	Empagliflozin Insulin resistance Myocardial infarction Dysglycaemia Cardiac magnetic resonance
Διαθέσιμο Online:	https://doi.org/10.1186/s12933-023-01950-0
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!